ConductScience.org, home

Paper9547669

Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study.

Stewart DJ and 5 others. Invest New Drugs, 1997. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study. Papers, record 9547669. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/9547669

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Multiple resistance modulators combined with carboplatin for resistant malignancies: a pilot study.
PubMed
Journal
Invest New Drugs
PubMed
Year
1997
PubMed
Publication types
Clinical Trial, Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.24
iCite
Revised in PubMed
2026-10-16
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stewart DJD J
2Goel RR
3Cripps MCM C
4Huan SS
5Yau JJ
6Verma SS

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
CarboplatinMajor topic
Drug Resistance, NeoplasmMajor topic
NeoplasmsMajor topic
Adult
Aged
Blood Viscosity
Female
Hematologic Diseases
Humans
Male
Middle Aged
Pilot Projects

Source PubMed

Download CSV of topics

References65

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13048763Resistance to cisplatin and analogues: mechanisms and potential clinical implications.Cancer Chemother Pharmacol1988https://conductscience.org/library/papers/3048763PubMed
26380349Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication.Angiology1984https://conductscience.org/library/papers/6380349PubMed
36422002Feasibility study of combining metronidazole with chemotherapy.J Clin Oncol1983https://conductscience.org/library/papers/6422002PubMed
43865352Antibacterial activity and pharmacokinetics of nitroimidazoles. A review.Scand J Infect Dis Suppl1985https://conductscience.org/library/papers/3865352PubMed
53698174
Altered pharmacokinetics in the mechanism of chemosensitization: effects of nitroimidazoles and other chemical modifiers on the pharmacokinetics, antitumour activity and acute toxicity of selected nitrogen mustards.
Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3698174PubMed
62118896Synergistic effect of cyclosporin A and verapamil in overcoming vincristine resistance of multidrug-resistant cultured human leukemia cells.Jpn J Cancer Res1990https://conductscience.org/library/papers/2118896PubMed
71478003Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.Clin Pharmacokinet1992https://conductscience.org/library/papers/1478003PubMed
88372807Dipyridamole enhancement of drug sensitivity in acute lymphoblastic leukemia cells.Am J Hematol1993https://conductscience.org/library/papers/8372807PubMed
97225286Cytotoxicity of metronidazole (Flagyl) and misonidazole (Ro-07-0582): enhancement by lactate.Br J Cancer1981https://conductscience.org/library/papers/7225286PubMed
109225947Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.Cancer Chemother Pharmacol1997https://conductscience.org/library/papers/9225947PubMed
118452101Doxorubicin plus metronidazole in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck.Am J Clin Oncol1993https://conductscience.org/library/papers/8452101PubMed
1237915595-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3791559PubMed
138174197Factors affecting human autopsy kidney-cortex and kidney-medulla platinum concentrations after cisplatin administration.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/8174197PubMed
141600596Synergistic interaction of cyclosporin A and verapamil on vincristine and daunorubicin resistance in multidrug-resistant human leukemia cells in vitro.Cancer Chemother Pharmacol1992https://conductscience.org/library/papers/1600596PubMed
157880744Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin.Br J Cancer1995https://conductscience.org/library/papers/7880744PubMed
162659168Non-chemotherapeutic agents that potentiate chemotherapy efficacy.Cancer Treat Rev1989https://conductscience.org/library/papers/2659168PubMed
178102639Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.J Clin Oncol1993https://conductscience.org/library/papers/8102639PubMed
183282647Determinants of tumor blood flow: a review.Cancer Res1988https://conductscience.org/library/papers/3282647PubMed
197987990Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.Cancer Chemother Pharmacol1994https://conductscience.org/library/papers/7987990PubMed
202170008Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II.Cancer Res1990https://conductscience.org/library/papers/2170008PubMed

See all 65 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
21983700A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.Invest New Drugs2012https://conductscience.org/library/papers/21983700PubMed
20047843Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.Crit Rev Oncol Hematol2010https://conductscience.org/library/papers/20047843PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/9547669

GET https://conductscience.org/api/papers/v1/9547669/references?page=2